跳至主要内容
临床试验/NCT02655692
NCT02655692已完成2 期

CAP-Ketamine for Antidepressant Resistant PTSD

VA Office of Research and Development3 个研究点 分布在 1 个国家目标入组 163 人开始时间: 2016年4月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
163
试验地点
3
主要终点
PTSD Checklist (PCL)

研究概览

简要总结

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

详细描述

In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of three treatment arms (placebo, low dose ketamine, high dose ketamine). Participants receive the study drug via intravenous infusion twice per week for 4-weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female Veterans or active duty military personnel between the ages of 18 and 70 years
  • diagnosis of PTSD
  • history of trialing one or more antidepressant medications with little to no PTSD symptom improvement
  • ability to provide written informed consent

排除标准

  • females who are currently pregnant or breastfeeding
  • current high risk for suicide
  • history of severe head injury

研究组 & 干预措施

Placebo

Placebo Comparator

Saline dose

干预措施: Placebo/Saline (Drug)

Low Dose Ketamine

Experimental

Low Dose Ketamine (.20 mg/kg)

干预措施: Ketamine (Drug)

High Dose Ketamine

Experimental

High Dose Ketamine (.50 mg/kg)

干预措施: Ketamine (Drug)

结局指标

主要结局

PTSD Checklist (PCL)

时间窗: Session 1 -Day 0

The PTSD Checklist (PCL) is a brief measure of the symptoms of Posttraumatic Stress Disorder (PTSD) to measure change in PTSD symptoms. The PCL-5 is a 20-item self-report measure, a total symptom severity score (range - 0-80) is obtained by summing the scores for each of the 20 items. (5-point Likert (0 = "Not at all" to 4 = "Extremely"). A total symptom severity score (range 0-80) with higher scores indicating greater severity for PTSD

The PTSD Checklist (PCL)

时间窗: Follow-up 7 - Day 56

The PTSD Checklist (PCL) is a brief measure of the symptoms of Posttraumatic Stress Disorder (PTSD) to measure change in PTSD symptoms. The PCL-5 is a 20-item self-report measure, a total symptom severity score (range - 0-80) is obtained by summing the scores for each of the 20 items. (5-point Likert (0 = "Not at all" to 4 = "Extremely"). A total symptom severity score (range 0-80) with higher scores indicating greater severity for PTSD

次要结局

  • Montgomery-Asberg Depression Rating Scale (MADRS)(Follow-up 7 - Day 56)

研究者

申办方类型
Fed
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

CAP-Ketamine for Antidepressant Resistant PTSD | 临床试验